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Modeling Contrast-imaging-assisted Optimal
Targeted Drug Delivery:
A Touchable Communication Channel
Estimation and Waveform Design Perspective
Yifan Chen, Yu Zhou, Ross Murch, and Panagiotis Kosmas
Abstract
To maximize the effect of treatment and minimize adverse effects on patients, we propose to optimize
nanorobots-assisted targeted drug delivery (TDD) for locoregional treatment of tumor from the perspective
of touchable communication channel estimation and waveform design. The drug particles are information
molecules; the loading/injection and unloading of the drug correspond to the transmitting and receiving
processes; the concentration-time profile of drug particles administered corresponds to the signalling
pulse. Given this analogy, we first propose to use contrast-enhanced microwave imaging (CMI) as a
pretherapeutic evaluation technique to determine the pharmacokinetic model of nanorobots-assisted TDD.
The CMI system applies an information-theoretic-criteria-based algorithm to estimate drug accumulation
in tumor, which is analogous to the estimation of channel impulse response in the communication
context. Subsequently, we present three strategies for optimal targeted therapies from the communication
waveform design perspective, which are based on minimization of residual drug molecules at the end
of each therapeutic session (i.e., inter-symbol interference), maximization of duration when the drug
intensity is above a prespecified threshold during each therapeutic session (i.e., non-fade duration), and
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minimization of average rate that a therapeutic operation is not received correctly at tumor [i.e., bit error
rate (BER)]. Finally, numerical examples are applied to demonstrate the effectiveness of the proposed
analytical framework.
Index Terms
Targeted drug delivery, contrast-enhanced microwave imaging, optimal targeted therapies, touchable
communication channel estimation and waveform design
I. INTRODUCTION
Nanoparticle-mediated targeted drug delivery (TDD) aims at enhancing locoregional therapies for
cancer treatment [1]. These nanoparticles are loaded with drugs and targeted to specific parts of the
body where there is solely diseased tissue, thereby avoiding interaction with healthy tissue. The main
constraints of the nanocarriers currently administered are the reliance on systemic circulation resulting
in only ∼ 2% of the total administered dose being deposited in the tumor, the lack of a propelling
force to penetrate the tumor beyond the diffusion limit, and the absence of a sensory-based displacement
capability to target the hypoxic zones [2]. Harnessing swarms of magneto-aerotactic bacteria such as the
Magnetococcus marinus strain MC-1 for delivering drug-containing nanoliposomes to the disease site can
significantly improve the therapeutic index of various nanocarriers in tumor regions as demonstrated in
[2]. It is crucial to obtain the appropriate concentration-time profile of the therapeutic agent to be injected
with respect to the developmental stage of the tumor in order to maximize the effect of treatment and to
minimize adverse effects on patients [3].
Molecular communication models can be applied to describe the TDD process [4]–[10]. In molecular
communication, an engineered miniature transmitter emits molecules, which propagate and are eventually
received by a miniature receiver. The information may be encoded in either the timing or the concentration
of molecules. The reception process often involves a chemical reaction between molecules (ligand) and
compliant receptors present on the receiver surface. Under this framework, the transmitting process for
a TDD system is the drug injection, the receiving process is the drug delivery at a specific target (e.g.,
tumor), and the channel is realized by the transport of drug particles in the blood stream. The signal
is the concentration-time profile of the therapeutic agent, which should be successfully received by the
tumor to decrease its size.
This analogy enables the analysis and design of TDD using classical communication tools [4]–[10].
By applying the queuing theory to model receptor saturation, thus treating it as a congestion problem
January 14, 2017 DRAFT
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in communication networks, the optimal drug release rate was estimated in [9] to guarantee that the
desired fraction of receptors bound to drug molecules without drug overloading. By modeling the
pharmacokinetics of TDD systems through the abstraction of molecular communication, including the
particle advection, diffusion, absorption, reaction, and adhesion as well as the impact of cardiovascular
diseases, the optimal drug injection rate was obtained in [7] to achieve a desired drug delivery rate. In
[3], optimal control techniques were applied to find the appropriate treatment and drug dose to decrease
the tumor size while minimizing total drug administered for antiangiogenic therapy, chemotherapy,
and radiotherapy. Finally, optimal shape of the antibody molecular structure was determined in [6] by
applying the antibody-mediated TDD system transport and antigen-binding kinetics, taking into account
the geometry of the antibody molecule, the electrochemical structure of the antibody-antigen complex, and
the physiology of the patient. Nevertheless, the existing works do not discuss how to obtain information
of the vascular, extracellular, and ligand-binding channels, which is necessary in order to apply the
proposed TDD strategies in real-life applications. Furthermore, none of the works has designed the drug
concentration-time profile from the perspective of communication waveform optimization, where the
transmission is organized in bursts of drug molecules (i.e., pulses denoting information bits).
The current contribution addresses the aforementioned problems by taking the following approaches.
Firstly, interfaces to connect the small-scale in vivo environment and the large-scale external environment
could be implemented under the paradigm of touchable communication as proposed in [8], [11]. The term
“touchable” means that the entire communication process can be controlled and tracked via interfaces.
Specifically, the in-messaging interfaces convert conventional electronic, magnetic, or optical signals
used by the large-scale device into commands to which nanorobots respond by performing subsequent
small-scale operations (e.g., through magnetotaxis directional control of MC-1 cells [2]), while the out-
messaging interfaces convert motion signals generated by nanorobots (e.g., releasing, swimming, and
targeting of nanorobots) to externally detectable and interpretable messages [12]. Contrast-enhanced
microwave imaging (CMI) can be employed as the out-messaging interface, where the cargo attached to
nanorobots is a microwave contrast agent such as carbon nanotubes, which can also serve as a therapeutic
agent in cancer treatment [13], [14]. Hence, the CMI technique is proposed for estimation of the TDD
pharmacokinetics (equivalently, the impulse response of the touchable communication channel), where
two signal-to-noise-ratio (SNR) sensitive information-theoretic criteria [15] are applied to determine the
drug disposition in tumor. This estimation step provides exact knowledge about the vascular channel
specific to the individual patient and the TDD process undergone, thereby alleviating the issue of wide
variety of vasculature across different patients.
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Secondly, a novel signal transmission scheme suitable for TDD based on the estimated channel response
and the on-off keying scheme is proposed. Three waveform design strategies are then suggested to
achieve minimum inter-symbol interference, maximum non-fade duration, and minimum average bit error
rate (BER). From the TDD perspective, these criteria yield low side-effects due to residual therapy
damaging some healthy tissues after each therapeutic session, long duration when the concentration of
drug molecules is sufficiently high, and low average rate that a therapeutic operation is not received
correctly at tumor, respectively.
It is worth emphasizing that both the two contributions mentioned above, namely, the CMI for approx-
imation of the TDD pharmacokinetics (channel estimation) and the optimal targeted therapies from the
communication perspective (waveform design) have not been covered in our previous works [8], [11],
which mainly focus on the general system architecture and channel modeling aspects.
The paper is organized as follows. In Section II, the system and channel models of touchable commu-
nication for optimal targeted therapies are investigated. In Section III, the CMI system for estimation of
the channel impulse response is presented. In Section IV, the signal transmission process is studied and
the waveform optimization strategies are introduced. Finally, Section V provides simulation studies of
TDD to demonstrate the principles of the analytical framework, with conclusions drawn in Section VI.
II. TOUCHABLE COMMUNICATION MODEL OF OPTIMAL TDD
The touchable communication model of TDD using drug-loaded nanorobots is illustrated in Fig. 1. The
information molecules are therapeutic agents. The binding of drug particles to a swarm of nanorobots such
as magneto-aerotactic bacteria and the injection of the swarm into the vascular network at a predefined
site are the transmitting process. The transmitted signal xT(t) is the amount of injected nanoparticles.
An external macro-unit generates a magnetic field; the nanorobots sense this field and move towards its
gradient via magnetotaxis. The propagation process is the touchable communication channel. When the
nanorobots reach the tumor, the drug particles will be removed from the vehicles and get assimilated into
the targeted issue allowing them to perform healing actions. The unloading operation corresponds to the
receiving process. The received signal xR(t) is the number of nanoparticles successfully discharged at
the tumor.
A. Signal Transmission Model
The amount of administered therapeutic agent must be carefully chosen to destroy the tumor, while
causing minimal injuries to healthy tissues due to leakage of drug molecules to the systemic flow. To
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address this issue, optimal control theories have been applied for antiangiogenic therapy, chemotherapy,
or radiotherapy [16], [17]. The adaptation of these conventional therapies to the case of magnetically
controlled drug-loaded nanoparticles was presented in [3]. Given the specific tumor growth model (e.g.,
the classical Hahnfeldt’s model [18] and its extension [3], [16]), the issue is to find an optimal control
input u to decrease the tumor size while minimizing total drug administered. A maximum drug intake
umax has to be enforced. Furthermore, a continuous administration of therapeutic agent has to be realized
[3].
From the communication perspective, the transmission process associated with the aforementioned drug
administration can be arranged using an on-off scheme consisting of multiple time slots. The period of
each slot is Tslot as illustrated in Fig. 1, which corresponds to the communication symbol duration. A
bit ‘0’ is denoted by the absence of molecule within a time slot. On the other hand, a bit ‘1’ is denoted
by a burst of molecules xT(t) over a short period equal to Tburst where Tburst ≤ Tslot. For normalized
xT(t) satisfying
∫ Tslot
0 xT(t)dt =
∫ Tburst
0 xT(t)dt = 1, the optimal control input ui emulated by the i
th
cluster of continuous emissions of drug molecules is:
ui =
∫ uiTslot
0
xT(t)dt
= ui
∫ Tburst
0
xT(t)dt.
(1)
As such, ui also denotes the number of bits over the ith cluster of continuous emissions. Furthermore,
the drug intake has to be saturated to an upper limit such that ui ≤ umax. This on-off scheme represents
both a clinically relevant drug administration process and a useful analytical framework for optimal
direct targeting therapy under the rubric of information transmission, which allows for application of the
classical communication performance measures such as inter-symbol interference, non-fade duration, and
BER to system design as to be made clear in the following sections.
B. Signal Reception Model
The signal reception process is characterized by the pharmacokinetics model, which describes how
the therapeutic agent is absorbed, distributed, and eliminated by the body and is commonly modeled
through the agent concentration in the sampled fluid (e.g., plasma or blood) at the host, xR(t). A
compartmental modeling analysis has been widely employed. For example, the compartment models
best-fit the concentration-time profiles of plasma temozolomide, which is an agent effective for treating
gliomas, in cerebrospinal fluid, normal brain, and brain tumor tissues in a rat orthotopic brain tumor
model [19]. The one-compartment model was applied in modeling the biodistribution of drug-loaded
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magnetic nanoparticles for the liver cancer [3], which is similar to the situation of nanorobots-assisted
TDD considered here. Under this circumstance, the input is equal to the dose at the initial time point 0
and becomes 0 thereafter. The concentration at time 0 corresponds to the dose divided by the volume of
the tumor, and the concentration decreases with time in an exponential manner.
Hence, the following agent concentration expression is derived:
xR(t) =
∫
τ
ρxT(τ) exp [−ζ(t− τ)] dτ, (2)
where ρ is the path loss from the injection site to the tumor and ζ is the drug clearance rate. The
path loss consists of three different components for touchable communication [8]: diffusion, branching,
and resorption. Each loss component reduces certain amount of nanorobots, and the overall attenuation
is obtained as the multiplication of these components. The diffusion occurs in the systemic flow due
to the random Brownian motions of nanorobots; the branching occurs at the entrance of the intended
daughter branch when the vessels are too slender to be imaged. The resorption quantifies the effect of
biodegradation on the amount of nanorobots consumed. Detailed derivations of the path loss ρ can be
found in [8]. As ρ is the multiplicative product of multiple independent random variables, it can be
approximated using a lognormal distribution by considering the central limit theorem in the log domain,
which is similar to the lognormal shadowing effect in classical wireless communications:
fρ(ρ) =
1
ρσρ
√
2π
e
−
(ln ρ−µρ)2
2σ2ρ . (3)
The two parameters µρ and σρ are, respectively, the mean and standard deviation of ln ρ. In addition,
the drug clearance rate describes how fast the drug is filtered out of the blood. The clearance is often
modeled as a constant for a specific biological system.
It is worth emphasizing that the model in (2) is concise with a small number of unknown parameters,
which is advantageous from the channel estimation perspective but may miss out on some useful details
about the vascular network. Thus, it is important for the TDD system designer to achieve a balanced
trade-off between channel model accuracy and estimation efficiency.
C. Out-messaging Interface Model
CMI can be employed as the out-messaging interface to estimate the total administered dose being
deposited in the tumor. The cargo attached to nanorobots is a microwave contrast agent such as carbon
nanotubes, ferroelectric nanoparticles, or magnetic nanoparticles, which can also be employed as a
therapeutic agent [13], [15], [20]–[22]. The contrast agent alters the dielectric property of the targeted
January 14, 2017 DRAFT
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tissue. Differential microwave imaging can then be applied to monitor backscatter signature over time,
which images temporal variation in tissue anomaly and provides information on the therapeutic index of
various nanoparticles in tumor. For illustration, breast cancer imaging is considered in the current work,
where a schematic diagram of the CMI system is shown in Fig. 2. The same figure also shows a tumorous
lesion buried in a cluttered background medium generated by tissue inhomogeneities.
Firstly, a single-pole Cole-Cole model is employed to describe the frequency dependence of the complex
permittivity, εbreast, of healthy breast tissue background medium over the band of interest (100 MHz to
20 GHz) [23]:
εbreast(ω) = F1 +
F2
1 + (jωF3)
1−F4
+
F5
jωε0
, (4)
where ω is the frequency in radian, ε0 is the permittivity of free space, and F1 ∼ F5 are fitting parameters.
Secondly, in terms of tumor permittivity, εtumor, it has been shown that there is a large variation in the
dielectric contrast between malignant and healthy breast tissues due to substantial heterogeneity and the
contrast ranges from no more than 10% to fivefold [24]. Furthermore, the complex permittivity of tumor
penetrated by nanorobots and attached with contrast medium nanocomposites can be approximated by
applying the classical Maxwell Garnett equation [25]:
ε˜tumor(ω) = εtumor(ω)
[εagent(ω) + 2εtumor(ω)] + 2Vagent [εagent(ω)− εtumor(ω)]
[εagent(ω) + 2εtumor(ω)]− Vagent [εagent(ω)− εtumor(ω)] , (5)
where ε˜tumor is the effective dielectric constant of tumor resulting from the inclusion of a volume fraction
Vagent of contrast agent nanoparticles with dielectric constant εagent.
The next step is to derive the waveforms scattered by tumor. It is assumed that the antennas are
immersed in a coupling medium with dielectric property matching the breast permittivity over the entire
frequency band [15]. Consider a tumor oriented parallel to multiple spatially diverse monostatic antenna
elements (i.e., the transmitter and receiver are collocated), A1, A2, · · · , AZ , generating equal electric
current line sources, i(t). The distances between the antennas and the tumor are r1 < r2 < · · · < rZ as
shown in Fig. 2. In the absence of a skin layer, the frequency-domain expression of the backscatter field
at Az (z = 1, 2, · · · , Z) is [26]:
I(ω)
[
ωµ0
4
+∞∑
ν=−∞
Kν(ω)H(2)ν (kbreastrz)
]
, (6)
where
Kν(ω) =
J ′ν
(
kbreastdtumor
2
)Jν ( k˜tumordtumor2 )−√ ε˜tumor(ω)εbreast(ω)Jν (kbreastdtumor2 )J ′ν
(
k˜tumordtumor
2
)
√
ε˜tumor(ω)
εbreast(ω)
H(2)ν
(
kbreastdtumor
2
)J ′ν ( k˜tumordtumor2 )−H(2)′ν (kbreastdtumor2 )Jν ( k˜tumordtumor2 ) . (7)
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The term µ0 is the permeability of free space, I is the frequency-domain representation of the current
source, H(2)ν is the νth-order Hankel function of the second kind, and Jν is the νth-order Bessel function.
The prime (′) denotes a derivative with respect to the argument of the function, dtumor is the diameter
of the tumor, and kbreast and k˜tumor are the wavenumbers for the tissue background medium and the
tumor mixed with nanoparticles, respectively. The propagation effects of a plane wave in the skin for the
round-trip distances traveled are separately accounted for. To include a skin layer with relative dielectric
constant εskin and conductivity σskin, the slab model is applied where the skin response is given by [27]:
Hskin(ω) =
{[
1−R2skin(ω)
]
e−j[kskin(ω)−kbreast(ω)]ξskin
1−R2skin(ω)e−j2kskin(ω)ξskin
}2
. (8)
The term Rskin is the Fresnel reflection coefficient of single reflection exterior to the skin layer, ξskin is
the thickness of the skin, and kskin is the wavenumber for skin. Subsequently, time-domain backscatter
signals are obtained from (6) and (8) by performing an inverse Fourier transform for a set of frequencies
spanning the band of interest:
otumor(t) = F
−1
{
I(ω)
[
ωµ0
4
+∞∑
ν=−∞
Kν(ω)H(2)ν (kbreastrz)
]
Hskin(ω)
}
= F−1 {I(ω)Htumor(ω)} ,
(9)
where Htumor is the frequency-domain channel response due to tumor and F−1 denotes inverse Fourier
transform. The backscatter signal due to tissue inhomogeneity can be obtained in a similar manner by
replacing the tumor dielectric properties with the tissue heterogeneity dielectric constant and conductivity.
Finally, it is important to determine the relationship between the agent concentration at the host, xR
in (2), and the volume fraction Vagent in (5). Let Dagent and Magent denote, respectively, the density and
mass of agent nanoparticles. Let Vtumor denote the tumor volume. It can be easily shown that Magent,
which is proportional to xR, is given by Magent = Dagent VtumorVagent1−Vagent . Consequently, in the real-life
situation of Vagent ≪ 1, xR is proportional to Vagent, which in turn determines the effective dielectric
constant of tumor ε˜tumor and the received backscatter signal otumor(t) in (9). Hence, by monitoring the
variation of otumor(t) over time due to drug deposition and elimination, the touchable communication
channel represented by the input-output relationship in (2) can be estimated as to be discussed in the
following section.
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III. ESTIMATION OF TDD PHARMOCOKINETIC MODEL
A. Estimation of Contrast Agent Concentration
The information-theoretic-criteria-based tumor detection algorithm in [15] is revisited here in the current
problem setting. Let iz(t) and oz(t) denote, respectively, the continuous-time excitation current and the
overall signal received by Az . Note that oz includes both the tumor response otumor,z given by (9) and
the tissue inhomogeneity response at Az . In the frequency domain, the following general relationship can
be obtained:
oz(t) =
∫ Tsc,z
0
hz(τ)iz(t− τ)dτ +wz(t), (10)
where hz is the continuous channel response, wz is the additive white Gaussian noise, and Tsc,z is the
length of the scattering channel. Sampling the received signal at rate f0 and defining the following
notations oz(m) = oz(m/f0), iz(m) = iz(m/f0), and wz(m) = wz(m/f0), the following discrete
representation is obtained:
oz(m) =
Lz−l∑
l=0
hz(l)iz(m− l) + wz(m), (11)
where hz(l) denotes the discrete channel response of hz(l/f0) and Lz denotes the order of the discrete
channel. Eq. (11) can be rewritten in the matrix form as
oz = Hziz +wz, (12)
where
oz = [oz((n− 1)(Lz +Mz − 1) + 1) · · · oz(n(Lz +Mz − 1))]T , (13)
Hz =


hz(0)
hz(0) hz(1)
. .
. ...
...
hz(0) hz(1) · · · hz(Mz − 1)
hz(1) hz(2) · · · hz(Mz)
...
... . .
.
hz(Lz − 2) hz(Lz − 1)
hz(Lz − 1)


, (14)
iz = [iz(nMz) · · · iz((n− 1)Mz + 1)]T , (15)
wz = [wz((n − 1)(Lz +Mz − 1) + 1) · · · wz(n(Lz +Mz − 1))]T . (16)
January 14, 2017 DRAFT
Page 9 of 43
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
SUBMITTED TO IEEE TRANSACTIONS ON NANOBIOSCIENCE 9
In (13)-(16), n = 1, 2, · · · , N is the index of each observation, Mz is the signal length, and oz , Hz , iz ,
and wz are the observation vector, the channel matrix, the source signal vector, and the noise vector,
respectively. The symbol
(
T
)
denotes matrix transpose.
Suppose that the delay introduced by a tumor is ℓz/f0 (0 < ℓz ≤ Lz − 1). the early-time responses
caused by healthy tissue heterogeneities that yield time-of-arrival less than ℓz/f0 can be distinguished
from the late-time responses due to the cancer itself, healthy tissue inhomogeneities, as well as mutual
interference between the cancer and other scattering centers with time-of-arrival no less than ℓz/f0. Drug
deposition in the cancer will distort the scattering channel responses caused by changes in the tumor
dielectric properties, and only the late responses will be influenced. The new channel matrix after infusion
of contrast agent is given by
H˜z = Hz +∆Hz, (17)
where the (i, j)th (i = 1, 2, · · · , Lz +Mz − 1; j = 1, 2, · · · ,Mz) entry of the perturbation matrix ∆Hz
is expressed as
∆Hz[i, j] =


0; if Hz[i, j] = 0
0; if Hz[i, j] = hz(l) and l < ℓz
∆hz(l); if Hz[i, j] = hz(l) and l ≥ ℓz
(18)
In (18), ∆hz(l) is a nonzero term summarizing the overall perturbation effect introduced to the lth tap
of the scattering channel.
CMI relies upon the difference between the backscatter responses with and without contrast medium
delivered to the cancer, viz.,
∆oz = o˜z − oz
= H˜ziz + w˜z − (Hziz +wz)
= ∆Hziz +∆wz,
(19)
where w˜z is the noise associated with the post-contrast scattered signals. Note that ∆wz = w˜z − wz
is also an additive white Gaussian noise. A close examination of (18) reveals that the first ℓz rows of
∆Hz (z = 1, 2, · · · , Z) are empty vectors. Apparently, rank (∆Hz) ≤ min(Lz+Mz−1−ℓz,Mz) = Mz
by noting that Lz ≥ ℓz +1. If we assume that the matrix ∆Hz is of full column rank and the covariance
matrix Iz = E{iz(t)i†z(t)}, where E denotes expectation, is nonsingular for all z, the rank of the covariance
matrix ∆Ψz = ∆HzIz∆H†z is Mz . The information-theoretic criteria such as the Akaike information
criterion or the minimum description length [15] can thus be applied to estimate the signal-to-noise ratio
(SNR) ηz = ‖∆Hziz‖2 /E
{
‖∆wz‖2
}
.
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Essentially, when an antenna Az is far away from the tumor and ηz is very low, the received differential
signal ∆oz only consists of the noise samples. Therefore, the estimated rank of △Ψz via the information-
theoretic criteria should be zero. On the contrary, if Az is near the tumor and ηz is sufficiently large,
there will be residual non-zero entries in ∆Hz. Therefore, the number of signals will be larger than zero.
Subsequently, at any observation time t, we identify the antenna index z∗(t) such that:
z∗(t) = max
{
z(t) ∈ {1, 2, · · · , Z} : rank (△Ψz(t)) > 0} . (20)
The corresponding normalized SNR is obtained as:
η¯z∗(t) =
rz∗(t)η
∗
rz∗(0)η∗
=
rz∗(t)
rz∗(0)
,
(21)
where η∗ represents the threshold SNR below which the CMI system is unable to detect the tumor. The
two terms rz∗(t) and rz∗(0) are the distances from the tumor to antennas Az∗(t) and Az∗(0), respectively,
where time 0 denotes the initial instant when nanorobots have just arrived at the tumor. These two
factors compensate for radial spreading resulting in decrease in amplitude of an electromagnetic wave as
it expands.
Finally, the normalized SNR η¯z∗(t) increases monotonically with the time-varying volume fraction
Vagent(t) [see also (5)]. Instead of using the exact but complex relationship between η¯z∗(t) and Vagent(t)
as presented in the previous section, the following simple yet versatile function is considered:
η¯z∗(t) =
[
Vagent(t)
Vagent(0)
]κ
[θ(t)− θ(t− 1)] , (22)
where Vagent(0) is the volume fraction at the initial time 0 and θ(·) is the Heaviside step function. For
κ→∞, Eq. (22) describes the case that η¯z∗(t) is more sensitive to Vagent(t) in the large volume fraction
regime. The case when η¯z∗(t) varies more significantly with Vagent(t) at low volume fraction is given by
κ→ 0.
As the information-theoretic method was successfully applied to more complicated breast phantoms
for tumor detection in [15], it is expected that the methodology would be applicable to a wide variety
of breast models for estimation of contrast agent concentration.
B. Estimation of Pharmocokinetic Model
Estimation of the pharmocokinetic model is achieved by sending Q impulses of contrast agent nanopar-
ticle and measuring the corresponding pilot channel responses at the tumor in terms of volume fraction.
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The volume fraction at the initial time Vagent(0) is proportional to the path loss ρ in (2) in the practical
scenario of Vagent(0) ≪ 1. Therefore, following (2), for the qth (q = 1, 2, · · · , Q) probing impulse, its
response in terms of volume fraction can be expressed as:
Vagent,q(t) = Vagent,q(0)e
−ζt + noise, (23)
where the subscript q denotes the model parameters for the qth impulse. In order to weight the measure-
ment points equally in least squares fitting, the objective is to minimize the function:
P∑
p=1
Vagent,q(tp) [lnVagent,q(tp)− lnVagent,q(0) + ζtp]2 (24)
over P measurement times for any q, which yields the following solutions [28]:
ln Vˆagent,q(0) =
∑P
p=1
[
t2pVagent,q(tp)
]∑P
p=1 [Vagent,q(tp) ln Vagent,q(tp)]∑P
p=1 Vagent,q(tp)
∑P
p=1
[
t2pVagent,q(tp)
]− [∑Pp=1 tpVagent,q(tp)]2
−
∑P
p=1 [tpVagent,q(tp)]
∑P
p=1 [tpVagent,q(tp) lnVagent,q(tp)]∑P
p=1 Vagent,q(tp)
∑P
p=1
[
t2pVagent,q(tp)
]− [∑Pp=1 tpVagent,q(tp)]2
(25)
and
ζˆq =−
∑P
p=1 Vagent,q(tp)
∑P
p=1 [tpVagent,q(tp) ln Vagent,q(tp)]∑P
p=1 Vagent,q(tp)
∑P
p=1
[
t2pVagent,q(tp)
]− [∑Pp=1 tpVagent,q(tp)]2
+
∑P
p=1 [tpVagent,q(tp)]
∑P
p=1 [Vagent,q(tp) lnVagent,q(tp)]∑P
p=1 Vagent,q(tp)
∑P
p=1
[
t2pVagent,q(tp)
]− [∑Pp=1 tpVagent,q(tp)]2
.
(26)
The symbol (ˆ·) denotes an estimated quantity. Note that as the drug elimination rate is a constant, the
final least-squares estimate of ζ is obtained as:
ζˆ =
1
Q
Q∑
q=1
ζˆq. (27)
Similar to the path loss ρ, the volume fraction Vagent(0) is also log-normally distributed. For determining
the maximum likelihood estimator of the lognormal distribution parameters µV and σV for Vagent(0), the
log-likelihood function is written as:
LLN
(
µV , σV
∣∣Vˆagent,1(0), Vˆagent,2(0), · · · , Vˆagent,Q(0))
= −
Q∑
q=1
ln Vˆagent,q(0) + LN
(
µV , σV
∣∣ ln Vˆagent,1(0), ln Vˆagent,2(0), · · · , ln Vˆagent,Q(0)) , (28)
where LN denotes the log-likelihood function of a normal distribution. Since the first term in (28) is
constant with regard to µV and σV , both logarithmic likelihood functions, LLN and LN , reach their
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maximum with the same µV and σV . Hence, using the formulas for the normal distribution maximum
likelihood parameter estimators, for the log-normal distribution it holds that [29]:
µˆV =
∑Q
q=1 ln Vˆagent,q(0)
Q
(29)
and
σˆ2V =
∑Q
q=1
[
ln Vˆagent,q(0)− µˆV
]2
Q
. (30)
IV. OPTIMIZATION OF CONCENTRATION-TIME PROFILE OF INJECTED DRUG MOLECULES
Three waveform design strategies are proposed in this section to achieve minimum inter-symbol
interference, maximum non-fade duration, and minimum BER. From the TDD perspective, these criteria
yield low side-effects caused by residual drug after each therapeutic session, long duration when the
drug dose is sufficiently high, and low rate that a therapeutic operation is interpreted wrongly at tumor,
respectively.
For simplicity, we assume that xT(t) is a boxcar function given by xT(t) = 1Tburst [θ(t)− θ(t− Tburst)].
The output signal is computed as:
xR(t) =


∫ t
0
ρ
Tburst
exp [−ζ(t− τ)] dτ, 0 ≤ t ≤ Tburst∫ Tburst
0
ρ
Tburst
exp [−ζ(t− τ)] dτ, t > Tburst
=


ρ[1−exp(−ζt)]
ζTburst
, 0 ≤ t ≤ Tburst
ρ{exp[−ζ(t−Tburst)]−exp(−ζt)}
ζTburst
, t > Tburst
(31)
Therefore, the probability that xR(t) at the end of each symbol duration, t = Tslot, is no greater than a
specified threshold xISI is derived as:
PISI = Pr {xR(Tslot) ≤ xISI}
= Pr
{
ρ ≤ ζTburstxISI
exp [−ζ (Tslot − Tburst)]− exp (−ζTslot)
}
=
1
2
+
1
2
erf


ln
{
ζTburstxISI
exp[−ζ(Tslot−Tburst)]−exp(−ζTslot)
}
− µρ
√
2σρ

 ,
(32)
by noting that Tslot > Tburst and ρ follows a lognormal distribution as expressed in (3). The term erf{·}
denotes the error function and the subscript ISI indicates that the threshold is related to: inter-symbol
interference.
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Subsequently, provided with another threshold xNFD and following (32), the duration when the contrast
agent concentration is above xNFD at each symbol time is expressed as
∆t = tu (xNFD)− tl (xNFD)
= −1
ζ
ln
{
ζTburstxNFD
ρ [exp (ζTburst)− 1]
}
−
[
−1
ζ
ln
(
1− ζTburstxNFD
ρ
)]
=
1
ζ
ln
{
[exp (ζTburst)− 1] (ρ− ζTburstxNFD)
ζTburstxNFD
}
,
(33)
where tu and tl are the intersections of the straight line xR(t) = xNFD and the curve drawn from (31).
The subscript NFD indicates that the threshold is related to non-fade duration. By applying (33) and (3),
the probability that ∆t is no less than a threshold ∆tNFD is given by:
PNFD = Pr {∆t ≥ ∆tNFD}
= Pr
{
ρ ≥ ζTburstxNFD exp (ζ∆tNFD)
exp (ζTburst)− 1
+ ζTburstxNFD
}
=
1
2
− 1
2
erf


ln
{
ζTburstxNFD exp(ζ∆tNFD)
exp(ζTburst)−1
+ ζTburstxNFD
}
− µρ
√
2σρ

 .
(34)
A. Maximization of PISI and PNFD
The inter-symbol interference and non-fade duration criteria for the touchable communication waveform
design aim at finding the values of Tburst such that PISI and PNFD in (32) and (34) are maximized.
In the situation that there is a tradeoff between PISI and PNFD, the Pareto efficiency can be applied. It
is a concept in multi-criteria optimization enabling all tradeoffs among the best combinations of multiple
criteria to be evaluated. The objective here is to maximize PISI and PNFD simultaneously, and the Pareto
frontier is defined as the set of choices of (PISI, PNFD) whereby any improvement with respect to PISI
comes at the expense of PNFD. Each point along that frontier represents a unique parameterization of the
transmitted signal xT(t) in terms of its pulse duration Tburst, so the associated Pareto optimality identifies
multiple Pareto solutions of (PISI, PNFD). Through this procedure one is able to investigate differences
among the multiple solutions that are able to optimize varying combinations of the two assessment
criteria.
The aforementioned Pareto efficiency strategy for waveform design can be formally expressed as
follows. Consider the system with function F : R[0,Tslot] → R2[0,1], where X is a compact set of feasible
decisions of Tburst in the space R[0,Tslot] = {x ∈ R|0 ≤ x ≤ Tslot} and Y is the feasible set of criterion
vectors (PISI, PNFD) in R2[0,1] = {y ∈ R|0 ≤ y ≤ 1} × {y ∈ R|0 ≤ y ≤ 1}. Larger criteria values are
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preferred to smaller ones. A point y′′ ∈ R2[0,1] is preferred to (strictly dominates) another point y′ ∈ R2[0,1],
written as y′′ ≻ y′. The Pareto frontier is thus written as:
{
y′ ∈ Y : {y′′ ∈ Y : y′′ ≻ y′, y′′ 6= y′} = ∅} . (35)
The Pareto optimum criterion aims at finding the set of Tburst such that the Pareto frontier is achieved.
B. Minimization of BER
As described in Section II-A, bits ‘1’ and ‘0’ are represented by a burst of drug molecules within a
time slot and the absence of molecules, respectively. It is thus assumed that the event of an erroneous
bit occurs under the following two conditions. When a bit ‘0’ is transmitted, the receiver (tumor) detects
the bit to be ‘1’ if the duration when the drug concentration is above xNFD is no less than ∆tNFD within
the symbol time. On the other hand, a bit ‘1’ is incorrectly detected as ‘0’ if this duration is less than
∆tNFD.
Subsequently, by ignoring counting errors at the receiver (i.e., all drug molecules delivered by nanoro-
bots to the tumor will be bound to cancer cell receptors), the BER can be derived as
Pe = Pr
{
bˆj = 1
∣∣bj = 0}Pr {bj = 0}+ Pr{bˆj = 0∣∣bj = 1}Pr {bj = 1}
≈ Pr
{
bˆj = 1
∣∣bj = 0; bj−1 = 1}Pr {bj = 0}Pr {bj−1 = 1}
+ Pr
{
bˆj = 0
∣∣bj = 1; bj−1 = 0}Pr {bj = 1}Pr {bj−1 = 0}
+ Pr
{
bˆj = 0
∣∣bj = 1; bj−1 = 1}Pr {bj = 1}Pr {bj−1 = 1} ,
(36)
where bj denotes the jth bit and Pr {·|·} is the conditional probability. Eq. (36) assumes that only the
(j−1)th bit has impact on the detection of the jth bit, because the concentration-time profiles for earlier
bits decay quickly with time.
The event
{
bˆj = 1
∣∣bj = 0; bj−1 = 1} occurs when the inter-symbol interference due to the (j − 1)th
bit is above a certain value, resulting in the duration when the drug concentration is above xNFD at the
jth bit is no less than ∆tNFD, i.e.,
tu (xNFD)− Tslot ≥ ∆tNFD
⇒ −1
ζ
ln
{
ζTburstxNFD
ρ [exp (ζTburst)− 1]
}
− Tslot ≥ ∆tNFD
⇒ ρ ≥ ζTburstxNFD
[exp (ζTburst)− 1] exp [−ζ (Tslot +∆tNFD)] .
(37)
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Consequently, the following conditional probability is given by
Pr
{
bˆj = 1
∣∣bj = 0; bj−1 = 1} = Pr
{
ρ ≥ ζTburstxNFD
[exp (ζTburst)− 1] exp [−ζ (Tslot +∆tNFD)]
}
=
1
2
− 1
2
erf


ln
{
ζTburstxNFD
[exp(ζTburst)−1] exp[−ζ(Tslot+∆tNFD)]
}
− µρ
√
2σρ

 .
(38)
Furthermore, the event
{
bˆj = 0
∣∣bj = 1; bj−1 = 0} is complementary to the non-fade event in (34)
because there is no inter-symbol interference from the (j − 1)th bit. Thus,
Pr
{
bˆj = 0
∣∣bj = 1; bj−1 = 0} = 1− PNFD. (39)
Next, the event
{
bˆj = 0
∣∣bj = 1; bj−1 = 1} occurs when the summation of the residual drug molecules
from the (j−1)th bit and the drug entering the tumor for the jth bit is too low to achieve correct detection
of bit 1. The two time instants when the drug concentration is equal to xNFD are first calculated by
applying (31) and assuming that the propagation channels for two consecutive bits are fully correlated.
For Tslot ≤ tl ≤ Tslot + Tburst, the following relationship is satisfied:
ρ {exp [−ζ (tl − Tburst)]− exp (−ζtl)}
ζTburst
+
ρ [1− exp [−ζ (tl − Tburst)]]
ζTburst
= xNFD, (40)
resulting in
tl = −1
ζ
ln
(
1− ζTburstxNFD
ρ
)
. (41)
On the other hand, for Tslot + Tburst < tu ≤ 2Tslot, we have
ρ {exp [−ζ (tu − Tburst)]− exp (−ζtu)}
ζTburst
+
ρ {exp [−ζ (tu − 2Tburst)]− exp [−ζ (tu − Tburst)]}
ζTburst
= xNFD,
(42)
giving rise to
tu = −1
ζ
ln
{
ζTburstxNFD
ρ [exp (2ζTburst)− 1]
}
. (43)
By applying the similar approach to (33) and (34), the following conditional probability is obtained:
Pr
{
bˆj = 0
∣∣bj = 1; bj−1 = 1} = Pr
{
ρ ≤ ζTburstxNFD exp (ζ∆tNFD)
exp (2ζTburst)− 1 + ζTburstxNFD
}
=
1
2
+
1
2
erf


ln
{
ζTburstxNFD exp(ζ∆tNFD)
exp(2ζTburst)−1
+ ζTburstxNFD
}
− µρ
√
2σρ

 .
(44)
Substituting (38), (39), and (44) into (36) yields the closed-form expression of BER.
Finally, the BER criterion for the touchable communication waveform design aims at finding the
optimal value of Tburst such that the BER in (36) is minimized.
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Because the contrast agent concentration is proportional to the volume fraction and only the latter is
estimated through the CMI system, the volume fraction will be used during the waveform design process.
V. NUMERICAL RESULTS AND ANALYSIS
A. System Settings for Simulation Study
A study case of CMI for optimal targeted therapies is presented in this section by applying the proposed
communication waveform design strategies. The CMI of breast cancer is investigated as illustrated in Fig.
2. A single 1 cm diameter cancerous mass is placed in the breast with multiple tissue inhomogeneities.
The dielectric properties of healthy breast tissues are governed by (4), where the “fat-medium” category
in [23] is considered with the following model parameters: F1 = 3.140, F2 = 1.708, F3 = 14.65 ps,
F4 = 0.061, and F5 = 0.036 S/m. The dielectric values of tumor tissue are assumed to be fivefold
those of healthy tissue across the whole band of interest [15], [24]. To emulate an uptake of contrast
agent nanoparticles in malignant tissue, the complex permittivity of the inclusion vary with the volume
fraction of drug molecules by following the mixture formula in (5). The contrast agent nanoparticles are
assumed to have exceptionally high microwave-frequency dielectric properties such as the functionalizing
CVD-synthesized carbon nanotubes via sonication in nitric and sulfuric acid investigated in [14]. The real
and imaginary parts of the complex permittivity of the agent are assumed to be 200 and 100, respectively,
over the band of interest [30]. The numerical phantom includes a skin layer with relative permittivity
36.0 and conductivity 4.0 S/m [26]. The thickness of the skin layer is 0.2 cm.
It is further assumed that antennas are immersed in a coupling medium with dielectric property matching
the breast permittivity over the entire frequency band [26], which can be achieved by using various
tissue-mimicking materials. The imaging system is comprised of an array of 41 elements located at
2 cm ∼ 42 cm from the tumor in an interval of 1 cm. Each antenna is driven with a modulated
Gaussian monocycle with the modulation frequency 1 GHz and pulse width 120 ps [15], [26]. The
reflected waveform is recorded at the same antenna (monostatic configuration). The backscatter signals
received at the antennas are computed by applying (9). The accumulation of drug molecules in the tumor
follows the input-output relationship in (2) and the corresponding impulse response in terms of volume
fraction is given by (23). It is supposed that the mean and standard deviation of the natural logarithm
of path loss from the injection site to the tumor are ln 0.2 and 0.2, respectively. We consider three
different elimination rates: ζ = 1.3 day−1, 1.5 day−1, and 1.7 day−1 [18]. The difference between
the postcontrast and precontrast signals is then computed for various concentrations of nanoparticles.
This clean differential waveform is first corrupted by a multiplicative complex Gaussian vector process
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representing measurement uncertainties. Subsequently, an additive white Gaussian noise vector is added
to the artifact-corrupted differential signal. The algorithm presented in Section III is then applied to
estimate the normalized SNR at each antenna and the time-varying volume fraction of drug molecules.
The final step is to determine the desirable values of Tburst for optimal targeted therapies by employing
the inter-symbol interference, non-fade duration, and BER waveform design criteria in Section IV.
B. Numerical Results
The dielectric constant and conductivity of tumor mixed with various volume fractions of drug mole-
cules are shown in Fig. 3. Both the dielectric properties increase with volume fraction. On the other
hand, the dielectric constant decreases and the conductivity increases as the frequency increases. Fig.
4 depicts the relationships between the normalized SNR η¯z∗(t) and the normalized volume fraction
Vagent(t)/Vagent(0) by applying the exact formulation in Section II-C and the approximation in (22)
with κ = 1.75, respectively. The approximation matches well the exact solution throughout the entire
range of Vagent(t)/Vagent(0).
Fig. 5 plots the relationships between the estimated rank of ∆Ψz in (20) and the SNR of differential
signal by utilizing the Akaike information criterion and the maximum description length, respectively. As
can be seen from this figure, the rank decreases as SNR reduces and the threshold SNRs can be obtained
when the rank has just turned to zero, which verifies the effectiveness of the algorithm presented in (20)
and (21). It is worth noting that the Akaike information criterion is more sensitive than the maximum
description length at the low SNR regime.
Fig. 6 shows 10 independent pilot channel responses measured by the CMI system. Due to the discrete
structure of the antenna array, the impulse responses are discretized as well. Also shown are the exact
mean response with µV = ln 0.2 and ζ = 1.5 and the estimated mean response with µˆV = ln 0.204 and
ζˆ = 1.5035. As demonstrated in Fig. 6, the exact model parameters of the lognormal distribution and
exponential clearance agree well with the estimated values. Furthermore, the estimated standard deviation
is σˆV = 0.1924, which is very close to the exact value of σV = 0.2.
The relationships between PISI, PNFD, and Tburst for various values of drug clearance rate ζ are
depicted in Fig. 7. As shown in this figure, as ζ decreases, PISI decreases leading to more severe inter-
symbol interference. On the contrary, PNFD increases with reduced ζ , indicating longer duration when
the drug concentration is above a threshold level during each symbol time. In general, PISI decreases
whereas PNFD increases as Tburst increases.
The Pareto frontiers of (PISI, PNFD) for various elimination rates are drawn in Fig. 8(a), which agree
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with the trend observed in Fig. 7. The zoomed-in versions of Fig. 8(a) for ζ = 1.3 day−1, ζ = 1.5 day−1,
and ζ = 1.7 day−1 are shown in Fig. 8(b)-(c), respectively. Noteworthily, in the regime of small PISI
(less than ∼ 0.002), PNFD increases with PISI and the Pareto optimality does not exist. In this case,
there is no tradeoff between these two probabilities and a single Tburst can be found to maximize both
the probabilities simultaneously.
Finally, Fig. 9 demonstrates the relationships between BER and Tburst for various values of elimination
rate ζ . It can be seen that overall, a larger ζ results in a larger BER, though there are some crossovers
when Tburst approaches 1 day. For all the clearance rates, the optimum Tburst that result in minimum
BERs can be acquired. Moreover, the optimum Tburst increases with ζ .
VI. CONCLUSION
A novel model of CMI-assisted optimal TDD from the perspective of touchable communication channel
estimation and waveform design has been proposed. The CMI technique has been employed as a prether-
apeutic evaluation technique to determine the pharmacokinetic model, where an information-theoretic-
criteria-based signal processing algorithm was applied to estimate drug accumulation in tumor. This step
is analogous to the estimation of channel impulse response in the classical communication systems. Three
TDD optimization strategies have been introduced. These strategies are based on minimization of residual
drug molecules at the end of each therapeutic session (i.e., inter-symbol interference), maximization of
duration that the drug intensity is above a prespecified threshold during each therapeutic session (i.e.,
non-fade duration), and minimization of average rate that a therapeutic operation is not received correctly
at tumor (i.e., BER). Finally, comprehensive numerical examples have been presented to demonstrate the
key processes and properties of the proposed analytical framework. The current work may provide useful
insight on realistic and clinically relevant design and implementation of touchable communication systems
for targeted therapies.
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Figure Captions
• Fig. 1: A schematic illustration of CMI for optimal targeted therapies from the touchable commu-
nication channel estimation and waveform design perspective.
• Fig. 2: CMI system setting for estimation of drug nanoparticle accumulation in the tumor. Each
antenna element has a different distance of separation from the tumor in order to estimate the
drug accumulation in the tumor through the SNR-sensitive information-theoretic-criteria-based signal
processing algorithm.
• Fig. 3: (a) Dielectric constant and (b) conductivity of tumor mixed with various volume fractions
of drug molecules.
• Fig. 4: Relationships between the normalized SNR and the normalized volume fraction by applying
the exact formulation in Section II-C and the approximation in (22), respectively.
• Fig. 5: Relationships between the estimated rank of ∆Ψz in (20) and the SNR of the differential
signal for two information-theoretic criteria.
• Fig. 6: 10 pilot channel impulse responses measured at the antenna array. Also shown are the
exact mean response with lnµV = ln 0.2 and ζ = 1.5 and the estimated mean response with
ln µˆV = ln 0.204 and ζˆ = 1.5035. The estimated standard deviation is σˆV = 0.1924, which is very
close to the exact value of σV = 0.2.
• Fig. 7: Relationships between PISI, PNFD, and Tburst for various elimination rates.
• Fig. 8: (a) Pareto frontiers of (PISI, PNFD) for various elimination rates, and the zoomed-in plots of
(a) for (b) ζ = 1.3 day−1, (c) ζ = 1.5 day−1, and (d) ζ = 1.7 day−1.
• Fig. 9: Relationships between BER and Tburst for various elimination rates.
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Fig. 1. A schematic illustration of CMI for optimal targeted therapies from the touchable communication channel estimation
and waveform design perspective.
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Fig. 2. CMI system setting for estimation of drug nanoparticle accumulation in the tumor. Each antenna element has a different
distance of separation from the tumor in order to estimate the drug accumulation in the tumor through the SNR-sensitive
information-theoretic-criteria-based signal processing algorithm.
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Fig. 3. (a) Dielectric constant and (b) conductivity of tumor mixed with various volume fractions of drug molecules.
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Fig. 4. Relationships between the normalized SNR and the normalized volume fraction by applying the exact formulation in
Section II-C and the approximation in (22), respectively.
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Fig. 5. Relationships between the estimated rank of ∆Ψz in (20) and the SNR of the differential signal for two information-
theoretic criteria.
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Fig. 6. 10 pilot channel impulse responses measured at the antenna array. Also shown are the exact mean response with
lnµV = ln 0.2 and ζ = 1.5 and the estimated mean response with ln µˆV = ln 0.204 and ζˆ = 1.5035. The estimated standard
deviation is σˆV = 0.1924, which is very close to the exact value of σV = 0.2.
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Fig. 7. Relationships between PISI, PNFD, and Tburst for various elimination rates.
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Fig. 9. Relationships between BER and Tburst for various elimination rates.
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Modeling Contrast-imaging-assisted Optimal
Targeted Drug Delivery:
A Touchable Communication Channel Estimation
and Waveform Design Perspective
Yifan Chen, Yu Zhou, Ross Murch, and Panagiotis Kosmas
Abstract—To maximize the effect of treatment and minimize
adverse effects on patients, we propose to optimize nanorobots-
assisted targeted drug delivery (TDD) for locoregional treatment
of tumor from the perspective of touchable communication
channel estimation and waveform design. The drug particles are
information molecules; the loading/injection and unloading of
the drug correspond to the transmitting and receiving processes;
the concentration-time profile of drug particles administered
corresponds to the signalling pulse. Given this analogy, we first
propose to use contrast-enhanced microwave imaging (CMI)
as a pretherapeutic evaluation technique to determine the
pharmacokinetic model of nanorobots-assisted TDD. The CMI
system applies an information-theoretic-criteria-based algorithm
to estimate drug accumulation in tumor, which is analogous to
the estimation of channel impulse response in the communication
context. Subsequently, we present three strategies for optimal
targeted therapies from the communication waveform design
perspective, which are based on minimization of residual drug
molecules at the end of each therapeutic session (i.e., inter-symbol
interference), maximization of duration when the drug intensity
is above a prespecified threshold during each therapeutic session
(i.e., non-fade duration), and minimization of average rate that
a therapeutic operation is not received correctly at tumor [i.e.,
bit error rate (BER)]. Finally, numerical examples are applied
to demonstrate the effectiveness of the proposed analytical
framework.
Index Terms—Targeted drug delivery, contrast-enhanced mi-
crowave imaging, optimal targeted therapies, touchable commu-
nication channel estimation and waveform design
I. INTRODUCTION
Nanoparticle-mediated targeted drug delivery (TDD) aims
at enhancing locoregional therapies for cancer treatment [1].
These nanoparticles are loaded with drugs and targeted to
specific parts of the body where there is solely diseased
tissue, thereby avoiding interaction with healthy tissue. The
main constraints of the nanocarriers currently administered
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are the reliance on systemic circulation resulting in only
∼ 2% of the total administered dose being deposited in the
tumor, the lack of a propelling force to penetrate the tumor
beyond the diffusion limit, and the absence of a sensory-
based displacement capability to target the hypoxic zones [2].
Harnessing swarms of magneto-aerotactic bacteria such as
the Magnetococcus marinus strain MC-1 for delivering drug-
containing nanoliposomes to the disease site can significantly
improve the therapeutic index of various nanocarriers in tumor
regions as demonstrated in [2]. It is crucial to obtain the
appropriate concentration-time profile of the therapeutic agent
to be injected with respect to the developmental stage of the
tumor in order to maximize the effect of treatment and to
minimize adverse effects on patients [3].
Molecular communication models can be applied to de-
scribe the TDD process [4]–[10]. In molecular communication,
an engineered miniature transmitter emits molecules, which
propagate and are eventually received by a miniature receiver.
The information may be encoded in either the timing or
the concentration of molecules. The reception process often
involves a chemical reaction between molecules (ligand) and
compliant receptors present on the receiver surface. Under this
framework, the transmitting process for a TDD system is the
drug injection, the receiving process is the drug delivery at a
specific target (e.g., tumor), and the channel is realized by the
transport of drug particles in the blood stream. The signal is
the concentration-time profile of the therapeutic agent, which
should be successfully received by the tumor to decrease its
size.
This analogy enables the analysis and design of TDD
using classical communication tools [4]–[10]. By applying
the queuing theory to model receptor saturation, thus treating
it as a congestion problem in communication networks, the
optimal drug release rate was estimated in [9] to guarantee
that the desired fraction of receptors bound to drug molecules
without drug overloading. By modeling the pharmacokinet-
ics of TDD systems through the abstraction of molecular
communication, including the particle advection, diffusion,
absorption, reaction, and adhesion as well as the impact of
cardiovascular diseases, the optimal drug injection rate was
obtained in [7] to achieve a desired drug delivery rate. In [3],
optimal control techniques were applied to find the appropriate
treatment and drug dose to decrease the tumor size while
minimizing total drug administered for antiangiogenic therapy,
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chemotherapy, and radiotherapy. Finally, optimal shape of
the antibody molecular structure was determined in [6] by
applying the antibody-mediated TDD system transport and
antigen-binding kinetics, taking into account the geometry of
the antibody molecule, the electrochemical structure of the
antibody-antigen complex, and the physiology of the patient.
Nevertheless, the existing works do not discuss how to obtain
information of the vascular, extracellular, and ligand-binding
channels, which is necessary in order to apply the proposed
TDD strategies in real-life applications. Furthermore, none of
the works has designed the drug concentration-time profile
from the perspective of communication waveform optimiza-
tion, where the transmission is organized in bursts of drug
molecules (i.e., pulses denoting information bits).
The current contribution addresses the aforementioned prob-
lems by taking the following approaches. Firstly, interfaces to
connect the small-scale in vivo environment and the large-
scale external environment could be implemented under the
paradigm of touchable communication as proposed in [8],
[11]. The term “touchable” means that the entire communi-
cation process can be controlled and tracked via interfaces.
Specifically, the in-messaging interfaces convert conventional
electronic, magnetic, or optical signals used by the large-
scale device into commands to which nanorobots respond by
performing subsequent small-scale operations (e.g., through
magnetotaxis directional control of MC-1 cells [2]), while
the out-messaging interfaces convert motion signals generated
by nanorobots (e.g., releasing, swimming, and targeting of
nanorobots) to externally detectable and interpretable mes-
sages [12]. Contrast-enhanced microwave imaging (CMI) can
be employed as the out-messaging interface, where the cargo
attached to nanorobots is a microwave contrast agent such as
carbon nanotubes, which can also serve as a therapeutic agent
in cancer treatment [13], [14]. Hence, the CMI technique is
proposed for estimation of the TDD pharmacokinetics (equiv-
alently, the impulse response of the touchable communica-
tion channel), where two signal-to-noise-ratio (SNR) sensitive
information-theoretic criteria [15] are applied to determine the
drug disposition in tumor. This estimation step provides exact
knowledge about the vascular channel specific to the individual
patient and the TDD process undergone, thereby alleviating the
issue of wide variety of vasculature across different patients.
Secondly, a novel signal transmission scheme suitable for
TDD based on the estimated channel response and the on-off
keying scheme is proposed. Three waveform design strategies
are then suggested to achieve minimum inter-symbol interfer-
ence, maximum non-fade duration, and minimum average bit
error rate (BER). From the TDD perspective, these criteria
yield low side-effects due to residual therapy damaging some
healthy tissues after each therapeutic session, long duration
when the concentration of drug molecules is sufficiently high,
and low average rate that a therapeutic operation is not
received correctly at tumor, respectively.
It is worth emphasizing that both the two contributions
mentioned above, namely, the CMI for approximation of the
TDD pharmacokinetics (channel estimation) and the optimal
targeted therapies from the communication perspective (wave-
form design) have not been covered in our previous works [8],
[11], which mainly focus on the general system architecture
and channel modeling aspects.
The paper is organized as follows. In Section II, the system
and channel models of touchable communication for optimal
targeted therapies are investigated. In Section III, the CMI
system for estimation of the channel impulse response is
presented. In Section IV, the signal transmission process is
studied and the waveform optimization strategies are intro-
duced. Finally, Section V provides simulation studies of TDD
to demonstrate the principles of the analytical framework, with
conclusions drawn in Section VI.
II. TOUCHABLE COMMUNICATION MODEL OF OPTIMAL
TDD
The touchable communication model of TDD using drug-
loaded nanorobots is illustrated in Fig. 1. The information
molecules are therapeutic agents. The binding of drug particles
to a swarm of nanorobots such as magneto-aerotactic bacteria
and the injection of the swarm into the vascular network at a
predefined site are the transmitting process. The transmitted
signal xT(t) is the amount of injected nanoparticles. An
external macro-unit generates a magnetic field; the nanorobots
sense this field and move towards its gradient via magneto-
taxis. The propagation process is the touchable communication
channel. When the nanorobots reach the tumor, the drug parti-
cles will be removed from the vehicles and get assimilated into
the targeted issue allowing them to perform healing actions.
The unloading operation corresponds to the receiving process.
The received signal xR(t) is the number of nanoparticles
successfully discharged at the tumor.
A. Signal Transmission Model
The amount of administered therapeutic agent must be care-
fully chosen to destroy the tumor, while causing minimal in-
juries to healthy tissues due to leakage of drug molecules to the
systemic flow. To address this issue, optimal control theories
have been applied for antiangiogenic therapy, chemotherapy, or
radiotherapy [16], [17]. The adaptation of these conventional
therapies to the case of magnetically controlled drug-loaded
nanoparticles was presented in [3]. Given the specific tumor
growth model (e.g., the classical Hahnfeldt’s model [18]
and its extension [3], [16]), the issue is to find an optimal
control input u to decrease the tumor size while minimizing
total drug administered. A maximum drug intake umax has
to be enforced. Furthermore, a continuous administration of
therapeutic agent has to be realized [3].
From the communication perspective, the transmission
process associated with the aforementioned drug adminis-
tration can be arranged using an on-off scheme consisting
of multiple time slots. The period of each slot is Tslot as
illustrated in Fig. 1, which corresponds to the communication
symbol duration. A bit ‘0’ is denoted by the absence of
molecule within a time slot. On the other hand, a bit ‘1’ is
denoted by a burst of molecules xT(t) over a short period
equal to Tburst where Tburst ≤ Tslot. For normalized xT(t)
satisfying
∫ Tslot
0
xT(t)dt =
∫ Tburst
0
xT(t)dt = 1, the optimal
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Fig. 1. A schematic illustration of CMI for optimal targeted therapies from the touchable communication channel estimation and waveform design perspective.
control input ui emulated by the ith cluster of continuous
emissions of drug molecules is:
ui =
∫ uiTslot
0
xT(t)dt
= ui
∫ Tburst
0
xT(t)dt.
(1)
As such, ui also denotes the number of bits over the ith
cluster of continuous emissions. Furthermore, the drug intake
has to be saturated to an upper limit such that ui ≤ umax.
This on-off scheme represents both a clinically relevant drug
administration process and a useful analytical framework for
optimal direct targeting therapy under the rubric of information
transmission, which allows for application of the classical
communication performance measures such as inter-symbol
interference, non-fade duration, and BER to system design as
to be made clear in the following sections.
B. Signal Reception Model
The signal reception process is characterized by the phar-
macokinetics model, which describes how the therapeutic
agent is absorbed, distributed, and eliminated by the body
and is commonly modeled through the agent concentration
in the sampled fluid (e.g., plasma or blood) at the host,
xR(t). A compartmental modeling analysis has been widely
employed. For example, the compartment models best-fit the
concentration-time profiles of plasma temozolomide, which
is an agent effective for treating gliomas, in cerebrospinal
fluid, normal brain, and brain tumor tissues in a rat orthotopic
brain tumor model [19]. The one-compartment model was ap-
plied in modeling the biodistribution of drug-loaded magnetic
nanoparticles for the liver cancer [3], which is similar to the
situation of nanorobots-assisted TDD considered here. Under
this circumstance, the input is equal to the dose at the initial
time point 0 and becomes 0 thereafter. The concentration at
time 0 corresponds to the dose divided by the volume of
the tumor, and the concentration decreases with time in an
exponential manner.
Hence, the following agent concentration expression is
derived:
xR(t) =
∫
τ
ρxT(τ) exp [−ζ(t− τ)] dτ, (2)
where ρ is the path loss from the injection site to the tumor
and ζ is the drug clearance rate. The path loss consists of
three different components for touchable communication [8]:
diffusion, branching, and resorption. Each loss component
reduces certain amount of nanorobots, and the overall atten-
uation is obtained as the multiplication of these components.
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The diffusion occurs in the systemic flow due to the random
Brownian motions of nanorobots; the branching occurs at the
entrance of the intended daughter branch when the vessels are
too slender to be imaged. The resorption quantifies the effect
of biodegradation on the amount of nanorobots consumed.
Detailed derivations of the path loss ρ can be found in [8].
As ρ is the multiplicative product of multiple independent
random variables, it can be approximated using a lognormal
distribution by considering the central limit theorem in the log
domain, which is similar to the lognormal shadowing effect in
classical wireless communications:
fρ(ρ) =
1
ρσρ
√
2π
e
−
(ln ρ−µρ)2
2σ2ρ . (3)
The two parameters µρ and σρ are, respectively, the mean
and standard deviation of ln ρ. In addition, the drug clearance
rate describes how fast the drug is filtered out of the blood.
The clearance is often modeled as a constant for a specific
biological system.
It is worth emphasizing that the model in (2) is concise
with a small number of unknown parameters, which is ad-
vantageous from the channel estimation perspective but may
miss out on some useful details about the vascular network.
Thus, it is important for the TDD system designer to achieve
a balanced trade-off between channel model accuracy and
estimation efficiency.
C. Out-messaging Interface Model
CMI can be employed as the out-messaging interface to
estimate the total administered dose being deposited in the tu-
mor. The cargo attached to nanorobots is a microwave contrast
agent such as carbon nanotubes, ferroelectric nanoparticles,
or magnetic nanoparticles, which can also be employed as
a therapeutic agent [13], [15], [20]–[22]. The contrast agent
alters the dielectric property of the targeted tissue. Differential
microwave imaging can then be applied to monitor backscatter
signature over time, which images temporal variation in tissue
anomaly and provides information on the therapeutic index of
various nanoparticles in tumor. For illustration, breast cancer
imaging is considered in the current work, where a schematic
diagram of the CMI system is shown in Fig. 2. The same figure
also shows a tumorous lesion buried in a cluttered background
medium generated by tissue inhomogeneities.
Firstly, a single-pole Cole-Cole model is employed to de-
scribe the frequency dependence of the complex permittivity,
εbreast, of healthy breast tissue background medium over the
band of interest (100 MHz to 20 GHz) [23]:
εbreast(ω) = F1 +
F2
1 + (jωF3)
1−F4
+
F5
jωε0
, (4)
where ω is the frequency in radian, ε0 is the permittivity of free
space, and F1 ∼ F5 are fitting parameters. Secondly, in terms
of tumor permittivity, εtumor, it has been shown that there is
a large variation in the dielectric contrast between malignant
and healthy breast tissues due to substantial heterogeneity and
the contrast ranges from no more than 10% to fivefold [24].
Furthermore, the complex permittivity of tumor penetrated by
Fig. 2. CMI system setting for estimation of drug nanoparticle accumulation
in the tumor. Each antenna element has a different distance of separation from
the tumor in order to estimate the drug accumulation in the tumor through
the SNR-sensitive information-theoretic-criteria-based signal processing algo-
rithm.
nanorobots and attached with contrast medium nanocompos-
ites can be approximated by applying the classical Maxwell
Garnett equation [25]:
ε˜tumor(ω) = εtumor(ω)×
[εagent(ω) + 2εtumor(ω)] + 2Vagent [εagent(ω)− εtumor(ω)]
[εagent(ω) + 2εtumor(ω)]− Vagent [εagent(ω)− εtumor(ω)] ,
(5)
where ε˜tumor is the effective dielectric constant of tumor
resulting from the inclusion of a volume fraction Vagent of
contrast agent nanoparticles with dielectric constant εagent.
The next step is to derive the waveforms scattered by
tumor. It is assumed that the antennas are immersed in a
coupling medium with dielectric property matching the breast
permittivity over the entire frequency band [15]. Consider a
tumor oriented parallel to multiple spatially diverse mono-
static antenna elements (i.e., the transmitter and receiver are
collocated), A1, A2, · · · , AZ , generating equal electric current
line sources, i(t). The distances between the antennas and the
tumor are r1 < r2 < · · · < rZ as shown in Fig. 2. In the
absence of a skin layer, the frequency-domain expression of
the backscatter field at Az (z = 1, 2, · · · , Z) is [26]:
I(ω)
[
ωµ0
4
+∞∑
ν=−∞
Kν(ω)H(2)ν (kbreastrz)
]
, (6)
where
Kν(ω) ={
J ′ν
(
kbreastdtumor
2
)
Jν
(
k˜tumordtumor
2
)
−
√
ε˜tumor(ω)
εbreast(ω)
Jν
(
kbreastdtumor
2
)
J ′ν
(
k˜tumordtumor
2
)}/
{√
ε˜tumor(ω)
εbreast(ω)
H(2)ν
(
kbreastdtumor
2
)
J ′ν
(
k˜tumordtumor
2
)
−H(2)′ν
(
kbreastdtumor
2
)
Jν
(
k˜tumordtumor
2
)}
.
(7)
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The term µ0 is the permeability of free space, I is the
frequency-domain representation of the current source, H(2)ν
is the νth-order Hankel function of the second kind, and Jν
is the νth-order Bessel function. The prime (′) denotes a
derivative with respect to the argument of the function, dtumor
is the diameter of the tumor, and kbreast and k˜tumor are the
wavenumbers for the tissue background medium and the tumor
mixed with nanoparticles, respectively. The propagation effects
of a plane wave in the skin for the round-trip distances traveled
are separately accounted for. To include a skin layer with
relative dielectric constant εskin and conductivity σskin, the
slab model is applied where the skin response is given by
[27]:
Hskin(ω) =
{[
1−R2skin(ω)
]
e−j[kskin(ω)−kbreast(ω)]ξskin
1−R2skin(ω)e−j2kskin(ω)ξskin
}2
.
(8)
The term Rskin is the Fresnel reflection coefficient of single
reflection exterior to the skin layer, ξskin is the thickness of
the skin, and kskin is the wavenumber for skin. Subsequently,
time-domain backscatter signals are obtained from (6) and
(8) by performing an inverse Fourier transform for a set of
frequencies spanning the band of interest:
otumor(t)
= F−1
{
I(ω)
[
ωµ0
4
+∞∑
ν=−∞
Kν(ω)H(2)ν (kbreastrz)
]
Hskin(ω)
}
= F−1 {I(ω)Htumor(ω)} ,
(9)
where Htumor is the frequency-domain channel response due
to tumor and F−1 denotes inverse Fourier transform. The
backscatter signal due to tissue inhomogeneity can be obtained
in a similar manner by replacing the tumor dielectric properties
with the tissue heterogeneity dielectric constant and conduc-
tivity.
Finally, it is important to determine the relationship between
the agent concentration at the host, xR in (2), and the vol-
ume fraction Vagent in (5). Let Dagent and Magent denote,
respectively, the density and mass of agent nanoparticles. Let
Vtumor denote the tumor volume. It can be easily shown that
Magent, which is proportional to xR, is given by Magent =
Dagent
VtumorVagent
1−Vagent
. Consequently, in the real-life situation of
Vagent ≪ 1, xR is proportional to Vagent, which in turn
determines the effective dielectric constant of tumor ε˜tumor
and the received backscatter signal otumor(t) in (9). Hence,
by monitoring the variation of otumor(t) over time due to
drug deposition and elimination, the touchable communication
channel represented by the input-output relationship in (2) can
be estimated as to be discussed in the following section.
III. ESTIMATION OF TDD PHARMOCOKINETIC MODEL
A. Estimation of Contrast Agent Concentration
The information-theoretic-criteria-based tumor detection al-
gorithm in [15] is revisited here in the current problem setting.
Let iz(t) and oz(t) denote, respectively, the continuous-time
excitation current and the overall signal received by Az . Note
that oz includes both the tumor response otumor,z given by (9)
and the tissue inhomogeneity response at Az . In the frequency
domain, the following general relationship can be obtained:
oz(t) =
∫ Tsc,z
0
hz(τ)iz(t− τ)dτ + wz(t), (10)
where hz is the continuous channel response, wz is the
additive white Gaussian noise, and Tsc,z is the length of the
scattering channel. Sampling the received signal at rate f0
and defining the following notations oz(m) = oz(m/f0),
iz(m) = iz(m/f0), and wz(m) = wz(m/f0), the following
discrete representation is obtained:
oz(m) =
Lz−l∑
l=0
hz(l)iz(m− l) + wz(m), (11)
where hz(l) denotes the discrete channel response of hz(l/f0)
and Lz denotes the order of the discrete channel. Eq. (11) can
be rewritten in the matrix form as
oz =Hziz +wz, (12)
where
oz =
[oz((n− 1)(Lz +Mz − 1) + 1) · · · oz(n(Lz +Mz − 1))]T ,
(13)
Hz =


hz(0)
hz(0) hz(1)
. .
. ...
...
hz(0) hz(1) · · · hz(Mz − 1)
hz(1) hz(2) · · · hz(Mz)
...
... . .
.
hz(Lz − 2) hz(Lz − 1)
hz(Lz − 1)


,
(14)
iz = [iz(nMz) · · · iz((n− 1)Mz + 1)]T , (15)
wz =
[wz((n− 1)(Lz +Mz − 1) + 1) · · · wz(n(Lz +Mz − 1))]T .
(16)
In (13)-(16), n = 1, 2, · · · , N is the index of each observation,
Mz is the signal length, and oz , Hz , iz , and wz are the
observation vector, the channel matrix, the source signal
vector, and the noise vector, respectively. The symbol
(
T
)
denotes matrix transpose.
Suppose that the delay introduced by a tumor is ℓz/f0 (0 <
ℓz ≤ Lz − 1). the early-time responses caused by healthy
tissue heterogeneities that yield time-of-arrival less than ℓz/f0
can be distinguished from the late-time responses due to the
cancer itself, healthy tissue inhomogeneities, as well as mutual
interference between the cancer and other scattering centers
with time-of-arrival no less than ℓz/f0. Drug deposition in the
cancer will distort the scattering channel responses caused by
changes in the tumor dielectric properties, and only the late
responses will be influenced. The new channel matrix after
infusion of contrast agent is given by
H˜z = Hz +∆Hz, (17)
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where the (i, j)th (i = 1, 2, · · · , Lz + Mz − 1; j =
1, 2, · · · ,Mz) entry of the perturbation matrix ∆Hz is ex-
pressed as
∆Hz[i, j] =


0; if Hz[i, j] = 0
0; if Hz[i, j] = hz(l) and l < ℓz
∆hz(l); if Hz[i, j] = hz(l) and l ≥ ℓz
(18)
In (18), ∆hz(l) is a nonzero term summarizing the overall
perturbation effect introduced to the lth tap of the scattering
channel.
CMI relies upon the difference between the backscatter
responses with and without contrast medium delivered to the
cancer, viz.,
∆oz = o˜z − oz
= H˜ziz + w˜z − (Hziz +wz)
= ∆Hziz +∆wz,
(19)
where w˜z is the noise associated with the post-contrast scat-
tered signals. Note that ∆wz = w˜z −wz is also an additive
white Gaussian noise. A close examination of (18) reveals that
the first ℓz rows of ∆Hz (z = 1, 2, · · · , Z) are empty vectors.
Apparently, rank (∆Hz) ≤ min(Lz+Mz−1−ℓz,Mz) =Mz
by noting that Lz ≥ ℓz + 1. If we assume that the matrix
∆Hz is of full column rank and the covariance matrix Iz =
E{iz(t)i†z(t)}, where E denotes expectation, is nonsingular for
all z, the rank of the covariance matrix ∆Ψz = ∆HzIz∆H†z
is Mz . The information-theoretic criteria such as the Akaike
information criterion or the minimum description length [15]
can thus be applied to estimate the signal-to-noise ratio (SNR)
ηz = ‖∆Hziz‖2 /E
{
‖∆wz‖2
}
.
Essentially, when an antenna Az is far away from the tumor
and ηz is very low, the received differential signal ∆oz only
consists of the noise samples. Therefore, the estimated rank of
△Ψz via the information-theoretic criteria should be zero. On
the contrary, if Az is near the tumor and ηz is sufficiently large,
there will be residual non-zero entries in ∆Hz . Therefore, the
number of signals will be larger than zero. Subsequently, at
any observation time t, we identify the antenna index z∗(t)
such that:
z∗(t) = max
{
z(t) ∈ {1, 2, · · · , Z} : rank (△Ψz(t)) > 0} .
(20)
The corresponding normalized SNR is obtained as:
η¯z∗(t) =
rz∗(t)η
∗
rz∗(0)η∗
=
rz∗(t)
rz∗(0)
,
(21)
where η∗ represents the threshold SNR below which the CMI
system is unable to detect the tumor. The two terms rz∗(t) and
rz∗(0) are the distances from the tumor to antennas Az∗(t) and
Az∗(0), respectively, where time 0 denotes the initial instant
when nanorobots have just arrived at the tumor. These two
factors compensate for radial spreading resulting in decrease
in amplitude of an electromagnetic wave as it expands.
Finally, the normalized SNR η¯z∗(t) increases monotonically
with the time-varying volume fraction Vagent(t) [see also (5)].
Instead of using the exact but complex relationship between
η¯z∗(t) and Vagent(t) as presented in the previous section, the
following simple yet versatile function is considered:
η¯z∗(t) =
[
Vagent(t)
Vagent(0)
]κ
[θ(t)− θ(t− 1)] , (22)
where Vagent(0) is the volume fraction at the initial time 0
and θ(·) is the Heaviside step function. For κ→∞, Eq. (22)
describes the case that η¯z∗(t) is more sensitive to Vagent(t) in
the large volume fraction regime. The case when η¯z∗(t) varies
more significantly with Vagent(t) at low volume fraction is
given by κ→ 0.
As the information-theoretic method was successfully ap-
plied to more complicated breast phantoms for tumor detec-
tion in [15], it is expected that the methodology would be
applicable to a wide variety of breast models for estimation
of contrast agent concentration.
B. Estimation of Pharmocokinetic Model
Estimation of the pharmocokinetic model is achieved by
sending Q impulses of contrast agent nanoparticle and mea-
suring the corresponding pilot channel responses at the tumor
in terms of volume fraction. The volume fraction at the initial
time Vagent(0) is proportional to the path loss ρ in (2) in the
practical scenario of Vagent(0)≪ 1. Therefore, following (2),
for the qth (q = 1, 2, · · · , Q) probing impulse, its response in
terms of volume fraction can be expressed as:
Vagent,q(t) = Vagent,q(0)e
−ζt + noise, (23)
where the subscript q denotes the model parameters for the qth
impulse. In order to weight the measurement points equally in
least squares fitting, the objective is to minimize the function:
P∑
p=1
Vagent,q(tp) [lnVagent,q(tp)− lnVagent,q(0) + ζtp]2 (24)
over P measurement times for any q, which yields the follow-
ing solutions [28]:
ln Vˆagent,q(0) =
P∑
p=1
[
t2pVagent,q(tp)
] P∑
p=1
[Vagent,q(tp) lnVagent,q(tp)]
/


P∑
p=1
Vagent,q(tp)
P∑
p=1
[
t2pVagent,q(tp)
]−
[
P∑
p=1
tpVagent,q(tp)
]2

−
P∑
p=1
[tpVagent,q(tp)]
P∑
p=1
[tpVagent,q(tp) lnVagent,q(tp)]
/


P∑
p=1
Vagent,q(tp)
P∑
p=1
[
t2pVagent,q(tp)
]−
[
P∑
p=1
tpVagent,q(tp)
]2

(25)
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and
ζˆq =
−
P∑
p=1
Vagent,q(tp)
P∑
p=1
[tpVagent,q(tp) ln Vagent,q(tp)]
/


P∑
p=1
Vagent,q(tp)
P∑
p=1
[
t2pVagent,q(tp)
] −
[
P∑
p=1
tpVagent,q(tp)
]2

+
P∑
p=1
[tpVagent,q(tp)]
P∑
p=1
[Vagent,q(tp) lnVagent,q(tp)]
/


P∑
p=1
Vagent,q(tp)
P∑
p=1
[
t2pVagent,q(tp)
] −
[
P∑
p=1
tpVagent,q(tp)
]2
 .
(26)
The symbol (ˆ·) denotes an estimated quantity. Note that as
the drug elimination rate is a constant, the final least-squares
estimate of ζ is obtained as:
ζˆ =
1
Q
Q∑
q=1
ζˆq. (27)
Similar to the path loss ρ, the volume fraction Vagent(0) is
also log-normally distributed. For determining the maximum
likelihood estimator of the lognormal distribution parameters
µV and σV for Vagent(0), the log-likelihood function is written
as:
LLN
(
µV , σV
∣∣Vˆagent,1(0), Vˆagent,2(0), · · · , Vˆagent,Q(0))
= −
Q∑
q=1
ln Vˆagent,q(0)
+ LN
(
µV , σV
∣∣ ln Vˆagent,1(0), ln Vˆagent,2(0), · · · , ln Vˆagent,Q(0)) ,
(28)
where LN denotes the log-likelihood function of a normal
distribution. Since the first term in (28) is constant with
regard to µV and σV , both logarithmic likelihood functions,
LLN and LN , reach their maximum with the same µV and
σV . Hence, using the formulas for the normal distribution
maximum likelihood parameter estimators, for the log-normal
distribution it holds that [29]:
µˆV =
∑Q
q=1 ln Vˆagent,q(0)
Q
(29)
and
σˆ2V =
∑Q
q=1
[
ln Vˆagent,q(0)− µˆV
]2
Q
. (30)
IV. OPTIMIZATION OF CONCENTRATION-TIME PROFILE OF
INJECTED DRUG MOLECULES
Three waveform design strategies are proposed in this sec-
tion to achieve minimum inter-symbol interference, maximum
non-fade duration, and minimum BER. From the TDD per-
spective, these criteria yield low side-effects caused by residual
drug after each therapeutic session, long duration when the
drug dose is sufficiently high, and low rate that a therapeutic
operation is interpreted wrongly at tumor, respectively.
For simplicity, we assume that xT(t) is a boxcar function
given by xT(t) = 1Tburst [θ(t) − θ(t− Tburst)]. The output
signal is computed as:
xR(t) =
{ ∫ t
0
ρ
Tburst
exp [−ζ(t− τ)] dτ, 0 ≤ t ≤ Tburst∫ Tburst
0
ρ
Tburst
exp [−ζ(t− τ)] dτ, t > Tburst
=
{
ρ[1−exp(−ζt)]
ζTburst
, 0 ≤ t ≤ Tburst
ρ{exp[−ζ(t−Tburst)]−exp(−ζt)}
ζTburst
, t > Tburst
(31)
Therefore, the probability that xR(t) at the end of each symbol
duration, t = Tslot, is no greater than a specified threshold xISI
is derived as:
PISI
= Pr {xR(Tslot) ≤ xISI}
= Pr
{
ρ ≤ ζTburstxISI
exp [−ζ (Tslot − Tburst)]− exp (−ζTslot)
}
=
1
2
+
1
2
erf


ln
{
ζTburstxISI
exp[−ζ(Tslot−Tburst)]−exp(−ζTslot)
}
− µρ
√
2σρ

 ,
(32)
by noting that Tslot > Tburst and ρ follows a lognormal
distribution as expressed in (3). The term erf{·} denotes the
error function and the subscript ISI indicates that the threshold
is related to: inter-symbol interference.
Subsequently, provided with another threshold xNFD and
following (32), the duration when the contrast agent concen-
tration is above xNFD at each symbol time is expressed as
∆t = tu (xNFD)− tl (xNFD)
= −1
ζ
ln
{
ζTburstxNFD
ρ [exp (ζTburst)− 1]
}
−
[
−1
ζ
ln
(
1− ζTburstxNFD
ρ
)]
=
1
ζ
ln
{
[exp (ζTburst)− 1] (ρ− ζTburstxNFD)
ζTburstxNFD
}
,
(33)
where tu and tl are the intersections of the straight line
xR(t) = xNFD and the curve drawn from (31). The subscript
NFD indicates that the threshold is related to non-fade dura-
tion. By applying (33) and (3), the probability that ∆t is no
less than a threshold ∆tNFD is given by:
PNFD
= Pr {∆t ≥ ∆tNFD}
= Pr
{
ρ ≥ ζTburstxNFD exp (ζ∆tNFD)
exp (ζTburst)− 1 + ζTburstxNFD
}
=
1
2
− 1
2
erf


ln
{
ζTburstxNFD exp(ζ∆tNFD)
exp(ζTburst)−1
+ ζTburstxNFD
}
− µρ
√
2σρ

 .
(34)
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A. Maximization of PISI and PNFD
The inter-symbol interference and non-fade duration criteria
for the touchable communication waveform design aim at
finding the values of Tburst such that PISI and PNFD in (32)
and (34) are maximized.
In the situation that there is a tradeoff between PISI and
PNFD, the Pareto efficiency can be applied. It is a concept
in multi-criteria optimization enabling all tradeoffs among the
best combinations of multiple criteria to be evaluated. The
objective here is to maximize PISI and PNFD simultaneously,
and the Pareto frontier is defined as the set of choices of
(PISI, PNFD) whereby any improvement with respect to PISI
comes at the expense of PNFD. Each point along that frontier
represents a unique parameterization of the transmitted signal
xT(t) in terms of its pulse duration Tburst, so the associ-
ated Pareto optimality identifies multiple Pareto solutions of
(PISI, PNFD). Through this procedure one is able to investigate
differences among the multiple solutions that are able to
optimize varying combinations of the two assessment criteria.
The aforementioned Pareto efficiency strategy for wave-
form design can be formally expressed as follows. Con-
sider the system with function F : R[0,Tslot] → R2[0,1],
where X is a compact set of feasible decisions of Tburst
in the space R[0,Tslot] = {x ∈ R|0 ≤ x ≤ Tslot} and Y is
the feasible set of criterion vectors (PISI, PNFD) in R2[0,1] =
{y ∈ R|0 ≤ y ≤ 1}× {y ∈ R|0 ≤ y ≤ 1}. Larger criteria val-
ues are preferred to smaller ones. A point y′′ ∈ R2[0,1] is
preferred to (strictly dominates) another point y′ ∈ R2[0,1],
written as y′′ ≻ y′. The Pareto frontier is thus written as:
{y′ ∈ Y : {y′′ ∈ Y : y′′ ≻ y′, y′′ 6= y′} = ∅} . (35)
The Pareto optimum criterion aims at finding the set of Tburst
such that the Pareto frontier is achieved.
B. Minimization of BER
As described in Section II-A, bits ‘1’ and ‘0’ are represented
by a burst of drug molecules within a time slot and the absence
of molecules, respectively. It is thus assumed that the event of
an erroneous bit occurs under the following two conditions.
When a bit ‘0’ is transmitted, the receiver (tumor) detects the
bit to be ‘1’ if the duration when the drug concentration is
above xNFD is no less than ∆tNFD within the symbol time.
On the other hand, a bit ‘1’ is incorrectly detected as ‘0’ if
this duration is less than ∆tNFD.
Subsequently, by ignoring counting errors at the receiver
(i.e., all drug molecules delivered by nanorobots to the tumor
will be bound to cancer cell receptors), the BER can be derived
as
Pe
= Pr
{
bˆj = 1
∣∣bj = 0}Pr {bj = 0}
+ Pr
{
bˆj = 0
∣∣bj = 1}Pr {bj = 1}
≈ Pr
{
bˆj = 1
∣∣bj = 0; bj−1 = 1}Pr {bj = 0}Pr {bj−1 = 1}
+ Pr
{
bˆj = 0
∣∣bj = 1; bj−1 = 0}Pr{bj = 1}Pr {bj−1 = 0}
+ Pr
{
bˆj = 0
∣∣bj = 1; bj−1 = 1}Pr{bj = 1}Pr {bj−1 = 1} ,
(36)
where bj denotes the jth bit and Pr {·|·} is the conditional
probability. Eq. (36) assumes that only the (j − 1)th bit
has impact on the detection of the jth bit, because the
concentration-time profiles for earlier bits decay quickly with
time.
The event
{
bˆj = 1
∣∣bj = 0; bj−1 = 1} occurs when the
inter-symbol interference due to the (j − 1)th bit is above
a certain value, resulting in the duration when the drug
concentration is above xNFD at the jth bit is no less than
∆tNFD, i.e.,
tu (xNFD)− Tslot ≥ ∆tNFD
⇒ −1
ζ
ln
{
ζTburstxNFD
ρ [exp (ζTburst)− 1]
}
− Tslot ≥ ∆tNFD
⇒ ρ ≥ ζTburstxNFD
[exp (ζTburst)− 1] exp [−ζ (Tslot +∆tNFD)] .
(37)
Consequently, the following conditional probability is given
by
Pr
{
bˆj = 1
∣∣bj = 0; bj−1 = 1}
= Pr
{
ρ ≥ ζTburstxNFD
[exp (ζTburst)− 1] exp [−ζ (Tslot +∆tNFD)]
}
=
1
2
− 1
2
erf


ln
{
ζTburstxNFD
[exp(ζTburst)−1] exp[−ζ(Tslot+∆tNFD)]
}
− µρ
√
2σρ

 .
(38)
Furthermore, the event
{
bˆj = 0
∣∣bj = 1; bj−1 = 0} is com-
plementary to the non-fade event in (34) because there is no
inter-symbol interference from the (j − 1)th bit. Thus,
Pr
{
bˆj = 0
∣∣bj = 1; bj−1 = 0} = 1− PNFD. (39)
Next, the event
{
bˆj = 0
∣∣bj = 1; bj−1 = 1} occurs when the
summation of the residual drug molecules from the (j − 1)th
bit and the drug entering the tumor for the jth bit is too low to
achieve correct detection of bit 1. The two time instants when
the drug concentration is equal to xNFD are first calculated
by applying (31) and assuming that the propagation channels
for two consecutive bits are fully correlated. For Tslot ≤ tl ≤
Tslot + Tburst, the following relationship is satisfied:
ρ {exp [−ζ (tl − Tburst)]− exp (−ζtl)}
ζTburst
+
ρ [1− exp [−ζ (tl − Tburst)]]
ζTburst
= xNFD,
(40)
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resulting in
tl = −1
ζ
ln
(
1− ζTburstxNFD
ρ
)
. (41)
On the other hand, for Tslot + Tburst < tu ≤ 2Tslot, we have
xNFD =
ρ {exp [−ζ (tu − Tburst)]− exp (−ζtu)}
ζTburst
+
ρ {exp [−ζ (tu − 2Tburst)]− exp [−ζ (tu − Tburst)]}
ζTburst
,
(42)
giving rise to
tu = −1
ζ
ln
{
ζTburstxNFD
ρ [exp (2ζTburst)− 1]
}
. (43)
By applying the similar approach to (33) and (34), the follow-
ing conditional probability is obtained:
Pr
{
bˆj = 0
∣∣bj = 1; bj−1 = 1}
= Pr
{
ρ ≤ ζTburstxNFD exp (ζ∆tNFD)
exp (2ζTburst)− 1 + ζTburstxNFD
}
=
1
2
+
1
2
erf


ln
{
ζTburstxNFD exp(ζ∆tNFD)
exp(2ζTburst)−1
+ ζTburstxNFD
}
− µρ
√
2σρ

 .
(44)
Substituting (38), (39), and (44) into (36) yields the closed-
form expression of BER.
Finally, the BER criterion for the touchable communication
waveform design aims at finding the optimal value of Tburst
such that the BER in (36) is minimized.
Because the contrast agent concentration is proportional to
the volume fraction and only the latter is estimated through
the CMI system, the volume fraction will be used during the
waveform design process.
V. NUMERICAL RESULTS AND ANALYSIS
A. System Settings for Simulation Study
A study case of CMI for optimal targeted therapies is
presented in this section by applying the proposed communi-
cation waveform design strategies. The CMI of breast cancer
is investigated as illustrated in Fig. 2. A single 1 cm diameter
cancerous mass is placed in the breast with multiple tissue
inhomogeneities. The dielectric properties of healthy breast
tissues are governed by (4), where the “fat-medium” category
in [23] is considered with the following model parameters:
F1 = 3.140, F2 = 1.708, F3 = 14.65 ps, F4 = 0.061,
and F5 = 0.036 S/m. The dielectric values of tumor tissue
are assumed to be fivefold those of healthy tissue across the
whole band of interest [15], [24]. To emulate an uptake of
contrast agent nanoparticles in malignant tissue, the complex
permittivity of the inclusion vary with the volume fraction
of drug molecules by following the mixture formula in (5).
The contrast agent nanoparticles are assumed to have excep-
tionally high microwave-frequency dielectric properties such
as the functionalizing CVD-synthesized carbon nanotubes via
sonication in nitric and sulfuric acid investigated in [14]. The
real and imaginary parts of the complex permittivity of the
agent are assumed to be 200 and 100, respectively, over the
band of interest [30]. The numerical phantom includes a skin
layer with relative permittivity 36.0 and conductivity 4.0 S/m
[26]. The thickness of the skin layer is 0.2 cm.
It is further assumed that antennas are immersed in a
coupling medium with dielectric property matching the breast
permittivity over the entire frequency band [26], which can
be achieved by using various tissue-mimicking materials. The
imaging system is comprised of an array of 41 elements
located at 2 cm ∼ 42 cm from the tumor in an interval
of 1 cm. Each antenna is driven with a modulated Gaussian
monocycle with the modulation frequency 1 GHz and pulse
width 120 ps [15], [26]. The reflected waveform is recorded at
the same antenna (monostatic configuration). The backscatter
signals received at the antennas are computed by applying
(9). The accumulation of drug molecules in the tumor follows
the input-output relationship in (2) and the corresponding
impulse response in terms of volume fraction is given by
(23). It is supposed that the mean and standard deviation
of the natural logarithm of path loss from the injection site
to the tumor are ln 0.2 and 0.2, respectively. We consider
three different elimination rates: ζ = 1.3 day−1, 1.5 day−1,
and 1.7 day−1 [18]. The difference between the postcontrast
and precontrast signals is then computed for various concen-
trations of nanoparticles. This clean differential waveform is
first corrupted by a multiplicative complex Gaussian vector
process representing measurement uncertainties. Subsequently,
an additive white Gaussian noise vector is added to the
artifact-corrupted differential signal. The algorithm presented
in Section III is then applied to estimate the normalized SNR
at each antenna and the time-varying volume fraction of drug
molecules.
The final step is to determine the desirable values of Tburst
for optimal targeted therapies by employing the inter-symbol
interference, non-fade duration, and BER waveform design
criteria in Section IV.
B. Numerical Results
The dielectric constant and conductivity of tumor mixed
with various volume fractions of drug molecules are shown
in Fig. 3. Both the dielectric properties increase with volume
fraction. On the other hand, the dielectric constant decreases
and the conductivity increases as the frequency increases.
Fig. 4 depicts the relationships between the normalized SNR
η¯z∗(t) and the normalized volume fraction Vagent(t)/Vagent(0)
by applying the exact formulation in Section II-C and the
approximation in (22) with κ = 1.75, respectively. The
approximation matches well the exact solution throughout the
entire range of Vagent(t)/Vagent(0).
Fig. 5 plots the relationships between the estimated rank of
∆Ψz in (20) and the SNR of differential signal by utilizing
the Akaike information criterion and the maximum description
length, respectively. As can be seen from this figure, the rank
decreases as SNR reduces and the threshold SNRs can be
obtained when the rank has just turned to zero, which verifies
Page 40 of 43
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
SUBMITTED TO IEEE TRANSACTIONS ON NANOBIOSCIENCE 10
0
5
10
0
0.1
0.2
20
25
30
35
40
45
Frequency (GHz)Volume Fraction
D
ie
le
ct
ric
 C
on
st
an
t
0
5
10
0
0.1
0.2
0
2
4
6
Frequency (GHz)Volume Fraction
Co
nd
uc
tiv
ity
 (S
/m
)
Fig. 3. (a) Dielectric constant and (b) conductivity of tumor mixed with
various volume fractions of drug molecules.
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the effectiveness of the algorithm presented in (20) and (21). It
is worth noting that the Akaike information criterion is more
sensitive than the maximum description length at the low SNR
regime.
Fig. 6 shows 10 independent pilot channel responses mea-
sured by the CMI system. Due to the discrete structure of the
antenna array, the impulse responses are discretized as well.
Also shown are the exact mean response with µV = ln 0.2 and
ζ = 1.5 and the estimated mean response with µˆV = ln 0.204
and ζˆ = 1.5035. As demonstrated in Fig. 6, the exact model
parameters of the lognormal distribution and exponential clear-
ance agree well with the estimated values. Furthermore, the
estimated standard deviation is σˆV = 0.1924, which is very
close to the exact value of σV = 0.2.
The relationships between PISI, PNFD, and Tburst for vari-
ous values of drug clearance rate ζ are depicted in Fig. 7. As
shown in this figure, as ζ decreases, PISI decreases leading
to more severe inter-symbol interference. On the contrary,
PNFD increases with reduced ζ, indicating longer duration
when the drug concentration is above a threshold level during
each symbol time. In general, PISI decreases whereas PNFD
increases as Tburst increases.
The Pareto frontiers of (PISI, PNFD) for various elimination
rates are drawn in Fig. 8(a), which agree with the trend
observed in Fig. 7. The zoomed-in versions of Fig. 8(a) for
ζ = 1.3 day−1, ζ = 1.5 day−1, and ζ = 1.7 day−1
are shown in Fig. 8(b)-(c), respectively. Noteworthily, in the
regime of small PISI (less than ∼ 0.002), PNFD increases
with PISI and the Pareto optimality does not exist. In this
case, there is no tradeoff between these two probabilities and
a single Tburst can be found to maximize both the probabilities
simultaneously.
Finally, Fig. 9 demonstrates the relationships between BER
and Tburst for various values of elimination rate ζ. It can be
seen that overall, a larger ζ results in a larger BER, though
there are some crossovers when Tburst approaches 1 day.
For all the clearance rates, the optimum Tburst that result
in minimum BERs can be acquired. Moreover, the optimum
Tburst increases with ζ.
VI. CONCLUSION
A novel model of CMI-assisted optimal TDD from the
perspective of touchable communication channel estimation
and waveform design has been proposed. The CMI technique
has been employed as a pretherapeutic evaluation technique to
determine the pharmacokinetic model, where an information-
theoretic-criteria-based signal processing algorithm was ap-
plied to estimate drug accumulation in tumor. This step is
analogous to the estimation of channel impulse response in
the classical communication systems. Three TDD optimiza-
tion strategies have been introduced. These strategies are
based on minimization of residual drug molecules at the end
of each therapeutic session (i.e., inter-symbol interference),
maximization of duration that the drug intensity is above a
prespecified threshold during each therapeutic session (i.e.,
non-fade duration), and minimization of average rate that a
therapeutic operation is not received correctly at tumor (i.e.,
BER). Finally, comprehensive numerical examples have been
presented to demonstrate the key processes and properties of
the proposed analytical framework. The current work may
provide useful insight on realistic and clinically relevant design
and implementation of touchable communication systems for
targeted therapies.
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